Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDITION III: Toujeo vs Lantus in Insulin-Naive T2DM
NCT01676220Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2012
- Primary completion
- Sep 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in HbA1c From Baseline to Month 6 Endpoint. Started Aug 2012; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01676220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01676220.